In an attempt to extend its dermatology capabilities to the US, Organon has agreed to acquire Dermavant Sciences, a Roivant company, for up to US$1.2 B. Through the deal, which involves a US$175 M upfront payment and up to US$1.025 B in milestones, Organon will gain access to Vtama® (tapinarof) cream, an FDA-approved, once-daily, non-steroidal, topical treatment of mild, moderate and severe plaque psoriasis in adults. The acquisition marks yet another deal announced by Organon as it attempts to expand its product portfolio and pipeline in women’s health and biosimilars.